Sarepta's $328.7M Q2 Looks Stable-But Investors Need Proof Before Buying the Comeback

Profitability returned, but revenue still needs to stabilize

Sarepta's second-quarter picture is a study in two different stories. The company reported net product revenue of $328.7 million and also posted GAAP and non-GAAP operating income of $13.3 million and $86.5 million. That helps explain the bull/bear divide: profitability came back, but the revenue base still looks too small to fully validate a recovery.

That matters even more under new leadership. Michael Severino took over as CEO in late July, so his first quarterly read comes with a simple test: can Sarepta convert operating discipline into steadier demand? Cost control clearly bought the company time, but it did not answer the bigger question.

ELEVIDYS and PMO held the line, but they did not prove a rebound

The quarter-to-quarter scorecard

You can read Sarepta's business in two parts: PMO as the base franchise and ELEVIDYS as the bigger swing factor. In the first quarter, the company reported $330.5 million of net product revenue, made up of $228.6 million of PMO net product revenue and $102.0 million of ELEVIDYS net product revenue. In the second quarter, net product revenue fell slightly to $328.7 million, including $230.6 million of PMO net product revenue and $98.1 million of ELEVIDYS net product revenue net product revenue of $328.7 million, consisting of $230.6 million of PMO net product revenue and $98.1 million of ELEVIDYS net product revenue.

PMO looks modestly firmer, moving from $228.6 million to $230.6 million. That is not a dramatic jump, but it is the kind of quiet stability investors want to see in the core franchise.

ELEVIDYS is the harder test. Revenue slipped from $102.0 million in Q1 to $98.1 million in Q2, which looks more like stabilization than a clear rebound. After a difficult stretch, that may be progress. But it is not enough on its own to close the comeback case.

The broader context still matters. Full-year 2025 net product revenue was $1,864.3 million, so Sarepta is not starting from zero. Even so, this quarter looks more stable than broken, not yet obviously strong.

What real-world activity looks like

This is where execution matters more than the headline number. In Q2 2025, Sarepta said ELEVIDYS shipments have resumed for ambulatory individuals and infusions are taking place for the ambulatory community. That matters because it shows the product is back in clinical use, at least for that patient group.

For now, the useful benchmark is whether patient flow and shipment activity remain intact from one reporting period to the next. A single quarter of stability is encouraging; sustained stability is what the market needs to believe the story.

A cleaner balance sheet and a practical pipeline keep the story alive

The stabilization debate is only part of the setup. The other question is whether Sarepta has created enough breathing room for the market to give management time to prove the narrative.

The balance sheet is less of a distraction

After the earlier cleanup, Sarepta told investors its financial position had improved. In its fourth-quarter and full-year 2025 release, management said the following refinancing of 2027 notes and corporate restructuring, overall financial position and capital structure strengthened to support full investment in our pipeline and marketed therapies. It also ended 2025 with nearly $1.0 billion in cash.

That does not guarantee a sales rebound, but it does remove some of the financing noise that has weighed on the stock. If investors were previously worried about liquidity and maturity pressure, that improvement alone can support a better tone even before revenue accelerates.

The pipeline still depends on clinical proof

The second lever is the pipeline. Management said it has significant opportunities ahead, including important data readouts in DM1 and FSHD. That keeps the long-term bull case alive because a broader, clinically useful pipeline can support a higher-value franchise than a one-product recovery story.

But the burden of proof is still on the data. Sarepta has already posted first Phase 1/2 data for SRP-1001 (FSHD1) and SRP-1003 (DM1) showing dose-dependent drug exposure, early biomarker effects, and favorable tolerability. That is a constructive start, not final evidence of commercial impact.

What to watch next

The next few weeks should clarify whether this is a durable stabilization or just a pause:

• the Q2 2026 Earnings Presentation posted with the release
• management's first full commentary on Sarepta Therapeutics Second Quarter 2026 Earnings Call
• any updates shared at Sarepta Therapeutics to Participate in Upcoming Investor Conferences

If those updates show steady commercial execution and more concrete pipeline utility, sentiment can improve from here. If not, the market is likely to stay cautious until revenue and treatment activity do more than hold the line.